The purpose of this guideline is to assist nuclear medicine practitioners in evaluating
patients for therapy with 131I (sodium iodide) for benign or malignant conditions of the …

This article presents an overview of the use of radioactive iodine (131-I) in the treatment of
patients who have well differentiated thyroid cancer. We review definitions; staging; the two …

THERAPY OF THYROID DISEASE WITH 131I• Silberstein et al. 1633 patients throughout
the United States. Existing practice guidelines will be reviewed for revision or renewal, as …

There is an abundance of evidence indicating that the oral administration of sodium 13II-
iodide is of value in the management of well-differentiated thyroid cancers. The first step in …

Background: Radiation safety is an essential component in the treatment of patients with
thyroid diseases by 131I. The American Thyroid Association created a task force to develop …

Discoveries related to thyroid immunology, especially concerning the thyroid-stimulating
hormone (TSH) receptor, may facilitate new immunologic approaches to the therapy of …

Awidely accepted therapy is 131I for patients with hyperthyroidism caused by Graves'
disease, toxic nodular disease, euthyroid multinodular goiters, and differentiated thyroid …

For almost five decades, 131I treatment of thyroid cancer has been based empirically on
administered activity rather than on actual radiation doses delivered. In 1983, we defined …

Nuclear Medicine Service and Medical Service, Hines Veterans Affairs Hospital, Hines,
Illinois; and Division of Nuclear Medicine, Department ofRadiology, and Department …

Radioactive iodine (RAI) therapy for hyperthyroidism was first used in 1941 by physicians at
Massachusetts General Hospital in Boston. 7, 58 The first nuclide used was 130I, which has …